A randomized phase III trial comparing sorafenib plus best supportive care (BSC) versus BSC alone in Child-Pugh B patients (pts) with advanced hepatocellular carcinoma (HCC): The BOOST study.
Bruno Daniele
Consultant or Advisory Role - Bayer
Honoraria - Bayer
Massimo Di Maio
Consultant or Advisory Role - Bayer
Honoraria - Bayer
Ciro Gallo
No relevant relationships to disclose
Antonio Gasbarrini
No relevant relationships to disclose
Giacomo Carteni
No relevant relationships to disclose
Giovan Giuseppe Di Costanzo
No relevant relationships to disclose
Antonio Craxi
No relevant relationships to disclose
Giuseppe Cabibbo
No relevant relationships to disclose
Luigi Bolondi
No relevant relationships to disclose
Alessandro Granito
No relevant relationships to disclose
Gabriele Missale
No relevant relationships to disclose
Antonio Frassoldati
No relevant relationships to disclose
Mario Angelico
No relevant relationships to disclose
Mario Roselli
No relevant relationships to disclose
Gennaro Daniele
No relevant relationships to disclose
Francesco Perrone
Honoraria - Bayer; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pfizer; Roche
Research Funding - Amgen; Bayer; Roche